Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 5
2009 4
2010 1
2011 3
2012 5
2013 3
2014 5
2015 7
2016 8
2017 5
2018 7
2019 6
2020 6
2021 10
2022 13
2023 11
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Necroptosis: A Pathogenic Negotiator in Human Diseases.
Chaouhan HS, Vinod C, Mahapatra N, Yu SH, Wang IK, Chen KB, Yu TM, Li CY. Chaouhan HS, et al. Among authors: yu tm. Int J Mol Sci. 2022 Oct 22;23(21):12714. doi: 10.3390/ijms232112714. Int J Mol Sci. 2022. PMID: 36361505 Free PMC article. Review.
Hepatointestinal complications in polycystic kidney disease.
Huang ST, Chuang YW, Yu TM, Lin CL, Jeng LB. Huang ST, et al. Among authors: yu tm. Oncotarget. 2017 Sep 15;8(46):80971-80980. doi: 10.18632/oncotarget.20901. eCollection 2017 Oct 6. Oncotarget. 2017. PMID: 29113359 Free PMC article.
Denosumab treatment and infection risks in patients with osteoporosis: propensity score matching analysis of a national-wide population-based cohort study.
Huang ST, Chiu TF, Chiu CW, Kao YN, Wang IK, Chang CT, Li CY, Sun CS, Lin CL, Yu TM, Kao CH. Huang ST, et al. Among authors: yu tm. Front Endocrinol (Lausanne). 2023 May 19;14:1182753. doi: 10.3389/fendo.2023.1182753. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37274347 Free PMC article.
88 results